Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

(HealthDay News) — Tulisokibart, a tumor necrosis factor-like cytokine 1A monoclonal antibody, is more effective in inducing clinical remission in patients with moderately to severely active ...

The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia and its ...

The European drugs regulator said on Friday it was reviewing anti hair-loss drugs, including Organon's Propecia, for the ...

Summit Therapeutics (NASDAQ: SMMT). This California-based biotech is developing a cancer medicine that has produced excellent clinical trial results in one area where Keytruda is the leader. Summit ...

BeiGene has officially launched its PD-1 cancer drug Tevimbra in the U.S. more than six months after receiving a much-delayed ...

Mark Cuban, Reid Hoffman and other big names in business joined with Vice President Harris’s campaign for the launch of ...

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced two ...

The European health regulator said on Friday it has started a review of anti hair-loss drugs, including Merck's Propecia, ...

Vice President Kamala Harris allies in the business community are trying to give her a boost over Donald Trump.

Jefferies analyst Brian Balchin maintained a Buy rating on Merck KGaA (0O14 – Research Report) today and set a price target of €180.00.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $144.12, ...